Abstract
Photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD) was evaluated using a supramolecular nanomedical device, that is, a novel dendritic photosensitizer (DP) encapsulated by a polymeric micelle formulation. The characteristic dendritic structure of the DP prevents aggregation of its core sensitizer, thereby inducing a highly effective photochemical reaction. With its highly selective accumulation on choroidal neovascularization (CNV) lesions, this treatment resulted in a remarkably efficacious CNV occlusion with minimal unfavorable phototoxicity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Drug Carriers / administration & dosage*
-
Drug Carriers / chemistry
-
Glaucoma, Neovascular / drug therapy
-
Glaucoma, Neovascular / metabolism*
-
Glaucoma, Neovascular / pathology
-
Macromolecular Substances / chemistry
-
Male
-
Nanotechnology / methods*
-
Photochemotherapy / methods*
-
Photosensitizing Agents / administration & dosage*
-
Photosensitizing Agents / pharmacokinetics*
-
Porphyrins / administration & dosage*
-
Porphyrins / chemistry
-
Rats
Substances
-
Drug Carriers
-
Macromolecular Substances
-
Photosensitizing Agents
-
Porphyrins